tiprankstipranks
Purple Biotech Unveils CAPTN-3 Cancer Therapy
Company Announcements

Purple Biotech Unveils CAPTN-3 Cancer Therapy

Purple Biotech (PPBT) has released an update.

Stay Ahead of the Market:

Purple Biotech Ltd., a clinical-stage bio-pharmaceutical company, is set to present its groundbreaking CAPTN-3 platform at the EORTC-NCI-AACR Symposium. The novel CAPTN-3 technology utilizes a tri-specific antibody approach to activate both T cells and NK cells, targeting the 5T4 antigen found in various solid tumors associated with poor clinical outcomes. This innovative therapy aims to enhance anti-tumor efficacy by inducing a strong localized immune response within the tumor microenvironment.

For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles